← Back to Search

Reduced-THC Cannabis for Cognitive Impairment from Cannabis Use (THC-YA Trial)

N/A
Waitlist Available
Led By Veronika Mesheriakova, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Between the ages of 21-25
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if switching to less potent THC products improves cognitive function in cannabis users aged 21-25.

Who is the study for?
This trial is for young adults aged 21-25 in San Francisco who use cannabis concentrates daily or almost daily, buying only from regulated stores. It's not for pregnant individuals or those regularly using drugs other than nicotine.
What is being tested?
The study tests if switching to cannabis with lower THC potency (15% and 35% reductions) improves cognitive function in frequent users. It includes blood and urine tests to assess THC consumption and its effects on cognition.
What are the potential side effects?
While the trial itself may not have direct side effects, using THC can lead to impaired memory, altered judgment, coordination issues, anxiety, paranoia, dizziness, dry mouth/eyes, increased appetite.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 25 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Delayed Matching-to-Sample Score
Change in One-Touch Stockings of Cambridge score
Change in Paired Associates Learning score
+4 more
Secondary study objectives
Baseline Urinary THC Excretion
Week 1 Urinary THC Excretion
Week 2 Urinary THC Excretion
+3 more
Other study objectives
Baseline Adapted Cannabis Purchase Task
Baseline Participant Reported Affect
Baseline Participant Reported Cannabis Use
+21 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: 35% THC Potency Reduction GroupExperimental Treatment1 Intervention
Participants will be incentivized to use THC products that are at least 35% less potent than baseline
Group II: 15% THC Potency Reduction GroupExperimental Treatment1 Intervention
Participants will be incentivized to use THC products that are at least 15% less potent than baseline

Find a Location

Who is running the clinical trial?

Cannabis Public Policy ConsultingUNKNOWN
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,840 Total Patients Enrolled
1 Trials studying Cannabis Use
48 Patients Enrolled for Cannabis Use
Veronika Mesheriakova, MDPrincipal InvestigatorUniversity of California, San Francisco
Michael Sofis, PhDPrincipal InvestigatorCannabis Public Policy Consulting
~57 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top